Table 3.

Subgroup analysis of ORR and DCR.

Subgroups	Number of studies	RR (95% CI)	Z	P	Heterogeneity
					I2	Ph
1.Objective response rate (ORR)
Drug delivery
Orally	15	1.27 (1.15, 1.39)	4.93	<0.00001	0%	0.96
Injection	17	1.20 (1.07, 1.35)	3.08	0.002	0%	0.94
PBC regimens
DDP-based chemotherapy regimen	10	1.25 (1.09, 1.44)	3.21	0.001	0%	0.79
OXA-based chemotherapy regimen	22	1.24 (1.13, 1.35)	4.81	<0.00001	0%	0.99
Treatment duration
≥8 weeks	22	1.27 (1.15, 1.40)	4.74	<0.00001	0%	0.98
<8 weeks	10	1.21 (1.08, 1.35)	3.36	0.0008	0%	0.88
2.Disease control rate (DCR)
Drug delivery
Orally	15	1.14 (1.07, 1.22)	4.03	<0.0001	27%	0.16
Injection	16	1.07 (1.02, 1.12)	2.73	0.006	0%	0.65
PBC regimens
DDP-based chemotherapy regimen	10	1.06 (1.00, 1.13)	2.06	0.04	0%	0.93
OXA-based chemotherapy regimen	21	1.13 (1.07, 1.20)	4.25	<0.0001	31%	0.09
Treatment duration
≥8 weeks	22	1.10 (1.05, 1.16)	4.14	<0.0001	6%	0.38
<8 weeks	9	1.09 (1.02, 1.18)	2.45	0.01	28%	0.19

RR, risk ratio; CI, confidence interval; DDP, cisplatin; OXA, oxaliplatin.